Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema

A retrospective cohort study at the Second People's Hospital of Jinan examined 76 hypertensive patients (76 eyes) with macular edema secondary to retinal vein occlusion. Patients were grouped by systemic blood pressure control status: Group A (under control), Group M (partially under control), and Group Z (out of control). All patients received intravitreal conbercept treatment.

The primary outcome was Best Corrected Visual Acuity (BCVA) at 1 month. The main finding was that BCVA was significantly better (p < 0.05) in Groups A and M compared to Group Z. The study did not report specific effect sizes, absolute numbers, or confidence intervals for this comparison.

Safety and tolerability data for conbercept were not reported. The study has several limitations: its retrospective design can only show association, not causation; the 1-month follow-up is very short for assessing macular edema outcomes; and key methodological details like specific BP targets and adjustment for confounders were not provided. Funding and conflicts of interest were also not reported.

For practice, this study underscores the clinical observation that co-managing systemic hypertension may be relevant in patients receiving anti-VEGF therapy for retinal vein occlusion. However, the evidence is preliminary and observational. Clinicians should interpret this as highlighting a potential area for integrated care rather than as proof that tight BP control directly improves anti-VEGF efficacy.